Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Lung Neoplasms 53Leukemia, Myeloid, Acute 52Neoplasm Metastasis 45Carcinoma, Non-Small-Cell Lung 40Prostatic Neoplasms 37Breast Neoplasms 36Multiple Myeloma 31Colorectal Neoplasms 29Pancreatic Neoplasms 26Carcinoma, Renal Cell 25Melanoma 23Ovarian Neoplasms 21Myelodysplastic Syndromes 21Triple Negative Breast Neoplasms 20Lymphoma 20Leukemia, Lymphocytic, Chronic, B-Cell 20Burkitt Lymphoma 19Lymphoma, Large B-Cell, Diffuse 18Precursor Cell Lymphoblastic Leukemia-Lymphoma 17Urinary Bladder Neoplasms 16Carcinoma, Hepatocellular 16Squamous Cell Carcinoma of Head and Neck 15Glioblastoma 15Fallopian Tube Neoplasms 14Oropharyngeal Neoplasms 13Glioma 13Endometrial Neoplasms 13Sarcoma 12Mouth Neoplasms 12Lymphoma, Non-Hodgkin 12

Interventions

ipatasertib 1Specimen Handling 1Sentinel Lymph Node Biopsy 1Ovariectomy 1Megestrol Acetate 1Magnetic Resonance Spectroscopy 1Hysterectomy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma × Specimen Handling × 90 days × Clear all
NCT05538897 2026-05-13

Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
96 enrolled
Gynecologic

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡